Transurethral needle ablation for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: outcome after 1 year

J Endourol. 2002 Mar;16(2):111-5. doi: 10.1089/089277902753619636.

Abstract

Purpose: The aims of the study were to evaluate short-term effects on lower urinary tract symptoms and uroflowmetry and assess side effects of transurethral needle ablation of the prostate (TUNA).

Patients and methods: Twenty-six men with a median age 68 years (range 53-77 years) were evaluated with symptom scores and voiding parameters before and at 3 and 12 months after TUNA. All treatments were performed in the outpatient department using topical anesthesia supplemented with sedoanalgesia.

Results: The International Prostate Symptom Score had decreased from 21.2 to 10.5 at 12 months postoperatively. Peak urinary flow was 10.9 mL/sec at baseline and was elevated to 13.7 mL/sec after 12 months. Residual urine volumes were unchanged. Postoperative urinary retention developed in 71% of the patients and had a mean duration of 6.3 (range 1-34) days. Postoperative perineal pain was noted by about half of the patients for the first 1 to 2 weeks. Painkillers were frequently used to reduce postoperative pain.

Conclusions: Transurethral needle ablation is a safe procedure suitable for the outpatient clinic. After short-term follow-up, statistically and clinically significant effects were observed on symptoms and uroflow. Long-term follow-up is mandatory to define the future role of this therapy.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pain, Postoperative
  • Prostate-Specific Antigen / blood
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / surgery*
  • Transurethral Resection of Prostate*
  • Treatment Outcome
  • Urodynamics
  • Urologic Diseases / etiology*
  • Urologic Diseases / prevention & control

Substances

  • Prostate-Specific Antigen